Benzinga

A veteran trader has said Bitcoin could rise as high as $600,000 in a best-case scenario, according to a report carried by Benzinga. The forecast implies a dramatic upside from current levels and is the latest in a series of bold long-term price predictions for the cryptocurrency from market commentators. Crypto watchers are weighing the call against Bitcoin's history of extreme volatility and past boom-and-bust cycles.

Kodiak Sciences announced that its experimental eye drug performs on par with Regeneron's established treatment, according to a Benzinga report. The claim, if supported by trial data, would position the biotech as a credible challenger in the competitive market for retinal disease therapies, where Regeneron's medicine has long been a dominant option.

AMC Entertainment shares are drawing attention as investors ask what is driving the movie theater chain's stock movement on Monday. Benzinga highlights the question, reflecting renewed interest in the company among retail traders who have long tracked its volatile price swings. No specific cause for Monday's move has been confirmed.